Background {#Sec1}
==========

The incidence of acute erythroid leukemia subtype (AEL) is rare, accounting for 5% of cases of acute myeloid leukemia (AML), characterized by a predominant erythroid population. AEL is generally associated with an aggressive clinical course. The outcome is usually dismal and transplantation will be recommended once complete remission (CR) has been achieved. The definition of AEL has undergone several revisions, including FAB (1976, 1985) and WHO (2001) edition \[[@CR1], [@CR2]\].

According to WHO 2008 edition, it is ruled as a case with ≥50% bone marrow (BM) erythroidprecursors and ≥ 20%myeloblasts in the non-erythroid cells (NEC). But the cases with 20% or more blasts and dysplasia involving at least 50% of cells in 2 or more lineages or myelodyspalstic syndrome (MDS) history are moved to the category of AML with MDS-related changes, even in the face of erythroid predominance \[[@CR3], [@CR4]\].

However, in the 2016 revision to the WHO classification, the subtype of AEL has been cancelled \[[@CR5]\]. Currently, myeloblasts are defined as the percentage of total marrow cells, not NEC. Therefore, the previous AEL cases are currently separated into AML or MDS according to new myeloblasts criteria. Those patients with the percentage of erythroid cells exceeded 50% and total myeloblasts exceeded 20% are diagnosed as AML, NOS. And those patients with the percentage of erythroid cells exceeded 50% and total myeloblasts were less than 20% are now diagnosed as MDS.

The main reason for the change is that AEL is similar with MDS, including morphologic characteristics, genetic profiles and prognosis by some groups \[[@CR6]--[@CR10]\]. But the above clinical studies were predominantly focused on the relationship among AEL, MDS with erythroid hyperplasia and the clinical significance of new myeloblasts criterion has not been evaluated yet. It was emphasized that the risk of cytogenetic could represent the most important prognostic factor better than myeloblasts percentage \[[@CR7], [@CR9], [@CR10]\]. With the aim to clarify the clinical significance of new classification, we respectively reviewed cases of 97 de novo diagnosed AEL according to 2008WHO classification, and now all the patients were diagnosed as AML or MDS according to new classification and they were compared in the multiple aspects of the clinical characteristics, cytogenetic and molecular genetics profiles. In addition, the relationship between treatment modalities and clinical outcome was investigated among the patients.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

All patients were diagnosed de novo acute erythroid/myeloid leukemia, while pure erythroid leukemia, AML with MDS-related changes and recurrent genetic abnormalities were precluded. All study regimens were in accordance with the Declaration of Helsinki and approved by the institutional review boards of the hospital. All patients were investigated by morphology, bone marrow aspiration and cytogenetic analysis. They all provided written informed consent for sample analyses. All the patients received DA (daunorubicin 40-45 mg/m^2^ on day1--3 and cytarabine 100-150 mg/m^2^ on day 1--7) or HAA (Homoharringtonine 2 mg/m^2^ on day 1--7,cytarabine 100-150 mg/m^2^ on day 1--7 and aclarubincin 20 mg/d on day 1--7) or HAD (Homoharringtonine 2 mg/m^2^ on day 1--7,cytarabine 100-150 mg/m^2^ on day 1--7 and daunorubicin 40 mg/m^2^ on day 1--3) as induction regimens. Once CR had been achieved, all the patients were suggested to receive allogeneic hematopoietic stem cell transplantation. If the patients cannot afford transplantation or cannot find suitable donor, they would receive HD-Ara-C (cytarabine 3 g/m^2^ per 12 h on day1--3) or MA (mitoxantrone 8 mg/m^2^ on day 1--3 and cytarabine 1.5 g/m^2^ per 12 h on day1--3) or DA (daunorubicin 40 mg/m^2^ on day 1--3 and cytarabine 1.5 g/m^2^ per 12 h on day1--3) as consolidation regimens. Clinical follow-up information, including overall survival (OS) and disease free survival (DFS) were retrieved from the electronic medical record and telephone communication. The median follow up was 21.9 month, the last follow-up time was 31/8/2016.

Conventional cytogenetics {#Sec4}
-------------------------

At least twenty metaphases were analyzed in chromosomal analysis. The results were recorded adopting the International system for Human Cytogenetic Nomenclature.

Molecular mutation analysis {#Sec5}
---------------------------

Gene mutation analysis was performed for *FLT3-ITD* (*n* = 69), *NPM*1 (*n* = 47), *CEBPA-BZIP* (*n* = 47), *CEBPA-TAD* (*n* = 47), *C-kit exon8* (*n* = 47), *C-kit exon17* (*n* = 47), *DNMT3A* (*n* = 33), *IDH1* (*n* = 16), *IDH2* (*n* = 16).

Statistical analyses {#Sec6}
--------------------

The Fisher exact test and χ^2^test were applied to variables. OS was defined as the time from diagnosis to death or last follow-up time. DFS was defined as the time from complete remission (CR) to relapse or death or last follow-up time. OS and DFS were estimated by Kaplan-Meier method. Survival curves were compared by the log-rank test. Multivariate analysis was performed by Cox proportional regression model. All tests were two-sided, accepting *p* value of 0.05 or below as indicating a statistically significant difference. Statistical analyses were performed by SPSS software version 18.0.

Results {#Sec7}
=======

Clinical characteristics, cytogenetic analysis and molecular mutations in MDS and AML subtypes {#Sec8}
----------------------------------------------------------------------------------------------

Total 97 patients were previously diagnosed as de novo AEL following WHO2008 criteria from 2004 to 2016. According to the new criteria, of them 65 patients were modified as MDS, 32 patients were diagnosed as AML, NOS. Therefore, majority of previous AEL were diagnosed as MDS according to the new classification criterion. The clinical features of total cases were summarized in Table [1](#Tab1){ref-type="table"}. As shown, incidence was higher in male in totally, particular MDS cases. The median age of total cases was 37 years old. And the age of MDS cases was older than that of AML cases (39 vs 33, *p* = 0.044). However, the median hemoglobin, white blood cell count, platelet count was nearly the same in both cases.Table 1Characteristics of 97 previous diagnosed de novo acute erythroid/myeloid leukemia patientsTotal\
*N* = 97MDS\
*N* = 65AML\
*N* = 32*P*Characteristics Sex, M/F60/3746/1914/180.01 Median age, y(range)37 (11--75)39 (11--70)33 (15--75)0.044 Median hemoglobin level, g/L(range)72 (36--141)71 (36--141)73 (41--119)0.615 Median WBC, ×10^9^/L(range)3.5 (0.61--62.9)3.36 (0.61--44.83)4.25 (1.21--62.9)0.201 Median platelet count, ×10^9^/L(range)49 (8--480)49 (9--480)46 (8--233)0.441Cytogenetic results, % Normal karyotype77.8 (70/90)76.3 (45/59)80.6 (25/31)0.635 Complex karyotype10 (9/90)11.9 (7/59)6.5 (2/31)0.657 Monosomy karyotype5.6 (5/90)5.1 (3/59)6.5 (2/31)1.0 Intermediate MRC category87.8 (79/90)86.4 (51/59)87.5 (28/32)1.0 Unfavorable MRC category12.2 (11/90)13.6 (8/59)9.4 (3/32)0.804 Good IPSS category78.9 (71/90)78.0 (46/59)80.6 (25/31)0.767 Intermediate IPSS category10 (9/90)10.2 (6/59)9.7 (3/31)1.0 Adverse IPSS category11.1 (10/90)11.9 (7/59)9.7 (3/31)1.0Molecular mutations, %  *NPM1* mutation19.1 (9/47)18.2 (6/33)21.4 (3/14)1.0  *FLT3-ITD* mutation4.3 (3/69)6.5 (3/46)4.3 (1/23)1.0  *CEBPA* single mutation6.4 (3/47)6.3 (2/32)6.7 (1/15)0.487  *CEBPA* double mutation6.4 (3/47)3.1 (1/32)13.3 (2/15)0.487  *DNMT3A* R882 mutation9.1 (3/33)11.5 (3/26)0 (0/7)1.0

Further, the chromosome karyotype were investigated. The results were available for 90 patients, including 59 MDS cases and 31 AML cases. Totally, the proportion of aberrant karyotype accounted for 20%, there were no difference in the proportion of normal karyotype, complex karyotype and monosomy karyotype between two subtypes. The proportions of each cytogenetic risk category using the IPSS and UKMRC schemes were also similar in both cases. Following MRC category, the majority of patients belonged to intermediate risk (87.8%), only 12.2% patients belonged to unfavorable risk.

Finally, some specific molecular mutations were further investigated. Only 69 cases were assessed for *FLT3-ITD* mutation, 47 cases were assessed for *NPM1* mutation, *CEBPA* mutation (*B-ZIP* domain and *TAD* domain), *C-kit* mutation, 33 cases were assessed for *DNMT3A* mutation. The incidence of the above mutations was 19.1% (*NPM1*), 4.3% (*FLT3-ITD*), 6.4% (*CEBPA single*), 6.4% (*CEBPA* double) and 9.1% (*DNMT3A*)separately. However, there were no difference in the incidence of these mutations in both cases. In addition, *C-kit* mutations were not found in these patients.

Survival according to MDS/AML subtypes and cytogenetic risk category {#Sec9}
--------------------------------------------------------------------

Survival of the total AEL patients was firstly investigated by MDS vs AML subtype, as presented in Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}, the 3-year OS was 56% (MDS subtype) and 64.4% (AML subtype) respectively. The median OS of MDS subtype was 44.6 months. And median OS of AML subtype had not been reached. The 3-year DFS was 75.1% (MDS subtype) and 60.7% (AML subtype) respectively. There were no difference between these two subtype in OS and DFS (*p* \> 0.05).Fig. 1Overall survival (**a**) and disease free survival (**b**) depending on MDS vs AML subtype Table 2Median 3-year overall survival (OS)/disease free survival (DFS) and median OS/DFS in months in previously diagnosed AEL patients depending on subtypes and cytogenetic risk group (MRC and IPSS criteria)ParameterMedian\
3-year OSMedian OS (Months)*P*Median\
3-year DFSMedian DFS (Months)*P*Subtype MDS56%44.60.56375.1%n.r.0.538 AML64.4%n.r.60.7%n.r.Cytogenetics Intermediate MRC category62.2%n.r\<0.000171.5%n.r0.008 Unfavorable MRC category12%5.0325%5.3 Good IPSS category56.9%n.r0.04569.3%n.r0.099 Intermediate IPSS category75%n.r85.7%n.r Adverse IPSS category13.3%11.825%5.33*Abbreviation*: *IPSS* International Prognostic Scoring System, *MRC* Medical Research Council

Further, the survival was explored according to cytogenetic category in all 97 patients. The MRC criteria and IPSS category were both investigated, as Table [2](#Tab2){ref-type="table"} showed, MRC category might be more suitable for distinguishing clinical outcome than IPSS category. As shown in the Fig. [2a](#Fig2){ref-type="fig"}, unfavorable karyotype was associated with an observable inferior 3-year OS compared to intermediate karyotype (12% vs 62.5%, *p* = 0.000), the results occurred both in MDS subtype and AML subtype (Fig. [2b](#Fig2){ref-type="fig"} and [c](#Fig2){ref-type="fig"}). However, the survival of same category in MDS subtype or AML subtype did not show any difference (Fig. [3](#Fig3){ref-type="fig"}). The 3-year OS of intermediate category in MDS and AML subtype was similar (59.7% vs 69.1%, *p* = 0.706), so were the median OS of unfavorable category (MDS 5.03 month vs AML 1.5 month, *p* \> 0.05).Fig. 2Overall survival depending on the cytogenetic category group (MRC criteria). Unfavorable category was associated with the significantly worse outcome compared with intermediate category. **a** in all previous diagnosed AEL patients (*n* = 90, *p* \< 0.0001); **b** in the current MDS subtypes (*n* = 59, *p* \< 0.0001); **c** in the current AML subtypes (*n* = 31, *p* \< 0.0001) Fig. 3Overall survival depending on the cytogenetic risk group (MRC criteria) in current MDS and AML subtypes. **a** in the intermediate category (*n* = 79); **b** in the unfavorable category (*n* = 11)

The prognostic factors in AEL {#Sec10}
-----------------------------

When we analyzed various clinical characteristics, including MDS vs AML subtype, cytogenetic and molecular mutations with regards to their ability to predict overall survival of all 97 patients (Table [3](#Tab3){ref-type="table"}), only cytogenetic risk and age were related. As shown in Additional file [1](#MOESM1){ref-type="media"}: Fig. S1, with the age increased, the survival decreased significantly. The 3-year OS of age \< 40, 40--60, \>60 was 65%, 52.3% and 33.3% respectively (*p* = 0.013). As shown in Additional file [2](#MOESM2){ref-type="media"}: Table S1, with the age increased, the proportion of unfavorable cytogenetic category increased sharply, the ratio was only 7.8% in age \< 40 group, but when age was older than 60, the ratio was 25%. However, MDS vs AML subtype, gender, WBC, *NPM1* mutation, *FLT3-ITD* mutation have little impact on the survival. Further, adopting multivariate analysis, the cytogenetic classification (*p* = 0.000, RR = 5.614) became the only independent parameter that implied outcome as shown in Table [3](#Tab3){ref-type="table"}, the results confirmed that cytogenetic, rather than arbitrary myeloblast percentage of total marrow cells, can better represent the outcome of patients.Table 3Analysis of prognostic parameters regarding overall survival in univariate and multivariate analyses in the 97 previous diagnosed AEL patientsVariableUnivariate analysisMultivariate analysis*PP*HR95% CI for HRUpperLowerAge(20 years increase)0.0130.11.5462.6000.920Gender0.4360.4620.6092.2810.163White blood count0.750.9080.9611.9010.486Platelet count0.4570.6081.5518.3090.289Hemoglobin level0.0920.2713.25626.6240.398MDS verse AML0.5630.9161.0593.0840.364Cytogenetic risk group(MRC)\<0.0001\<0.0015.61413.1372.399*NPM1* mutation0.0580.1540.2231.7570.028*FLT3-ITD* mutation0.5930.7361.46113.1890.162*HR* hazard ratios, *CI* confidence intervals

The effect of transplantation in AEL {#Sec11}
------------------------------------

The influence of the treatment modalities was also investigated. Of total 97 patients, 70 patients received chemotherapy or best supportive treatment as their treatment choice. 27 patients received transplantation eventually after chemotherapy, of them 25 patients attained complete remission (CR) before transplantation. The distribution of treatment choice in clinical characteristics such as cytogenetic category, age group and MDS vs AML subtype were listed in Table [4](#Tab4){ref-type="table"}. In the intermediate cytogenetic risk, 31.6% of patients received transplantation. The proportion of transplantation patients in the age \< 40 and 40--60 group was 40.7% and 14.7%. The proportion of transplantation cases in AML or MDS subtype patients was similar, 25% (AML) vs 29.2% (MDS).Table 4The proportion of treatment modalities (no transplantation vs transplantation) in different cytogenetic category, age group and disease subtypesno transplantationtransplantationCytogenetic categoryIntermediate, *n* = 7968.4% (54/79)31.6% (25/79)Unfavorable, *n* = 11100% (11/11)0 (0/11)Age group\<40, *n* = 5459.3% (32/54)40.7% (22/54)40--60, *n* = 3485.3% (29/34)14.7% (5/34)\>60, *n* = 9100% (9/9)0 (0/9)SubtypesMDS, *n* = 6570.8% (46/65)29.2% (19/65)AML, *n* = 3275% (24/32)25% (8/32)

The survival of transplantation cases and chemotherapy/supportive treatment cases were shown in Fig. [4](#Fig4){ref-type="fig"}. Totally, the 3-year OS of the two groups were 67.1% and 54.6%, there was no significant difference (*p* = 0.114) (Fig. [4a](#Fig4){ref-type="fig"}). The survival of transplantation was further explored in MDS and AML subtype. In MDS subtype, the 3-year OS of two groups was 68.9% and 49.7% respectively (*p* = 0.068) (Fig. [4b](#Fig4){ref-type="fig"}). However, in AML subtype, the difference of 3-year OS was similar (62.5% vs 62.6%, *p* \> 0.05) (Fig. [4c](#Fig4){ref-type="fig"}). Further analysis showed that when the cytogenetic risk of patients belonged to MRC intermediate risk and age were below 40 years-old, the patients who received chemotherapy without transplantation had a similar survival compared with the patients who underwent transplantation (3-year OS: 67.2% vs 68.5%) as Fig. [4d](#Fig4){ref-type="fig"} shown.Fig. 4Overall survival depending on treatment modalities (transplantation vs no transplantation). **a** in the previous diagnosed 97 AEL patients (*p* = 0.114); **b** in the current 67 MDS patients (*p* = 0.068); **c** in the current AML patients (*p* = 0.684); **d** in those whose cytogenetic risk belonged to intermediate category and age were below 40 years-old (*p* = 0.705)

Discussion {#Sec12}
==========

In our study, previously diagnosed AEL cases were modified as AML subtype or MDS subtype following the new classification. The majority of AEL cases were diagnosed as MDS, accounting for 2/3 of the patients. After comparing the clinical characteristics, cytogenetic risk and molecular mutation of two subtypes, we found that there were no difference between two subtypes except for male/female ratio and age. When the survival of previously AEL cases was analyzed, only MRC cytogenetic category and age were correlated with survival, regardless of MDS/AML subtype. Transplantation was beneficial for all the patients, particular MDS patients. However, when the patients whose age were below 40 and cytogenetic risk belonged to the intermediate category, the survival of those who only receive chemotherapy was similar to that of the patients who received transplantation eventually. Therefore, taking expensive cost and severe complication of transplantation into consideration, it was suggested this population of patients could receive chemotherapy as main treatment choice.

In contrast to Western studies, the most noticeable point of our study was that the median age of our patients was 37-years old, much younger than the data of Western studies \[[@CR11], [@CR12]\]. Owing to younger age and less unfavorable cytogenetic, the 3-year OS of our patients could reach 50--60%, better than the survival of published articles of AEL.

As we known, there is no specific chromosome abnormality described in AEL. Complex karyotypes with multiple structure abnormality are common, −5/del(5q), −7/del(7q) and +8 were the most common subtypes \[[@CR13]\]. The impact of cytogenetic on survival of AEL had been confirmed by other colleagues \[[@CR7], [@CR9]\]. The conclusion was further confirmed by our study in the application of previous diagnosed AEL patients. In addition, MRC category was better than IPSS category for distinguishing the outcomes, but that was against by Liu CJ et al. \[[@CR14]\] IPSS category was not suitable for the distinction between good and intermediate category.

There were also some disadvantages in the study. The samples for the assessment of molecular mutations were not huge enough. Few cases had been assessed at the molecular level owing to the rarity of AEL in Western countries. Recently, the impact of molecular mutations on the survival has been intrigued more and more attentions. It was believed that AEL could be distinguished by cytogenetic and molecular genetic characteristics, such as *RUNX1* and *TP53* mutations that implied the worse outcome and *NPM1* mutation that implied better outcome \[[@CR7]\]. But in our study, *FLT3-ITD*, *NPM1*mutation did not show any significance for prognosis to date. Therefore, there was still a long time for us to accumulate the samples to clarify the issue.

To date, there were few articles investigating the application of new classification on the previous diagnosed AEL cases. Following WHO new scheme, the subtype of previous AEL was removed and substituted for AML or MDS. In our study, after comparing the two subtypes, there was no obvious difference in reality, but giving the relationship among AEL, AML --MRC with erythroid hyperplasia and MDS with erythroid hyperplasia by a serial of researches \[[@CR6]--[@CR10], [@CR15]\], it was still reasonable to adopt new classification.

In our impression, it has a dismal outcome for AEL patients. Stem cell transplantation can substantially improve the outcome of the disease, with 5-year leukemia-free survival reaching approximately 60% after HLA-identical sibling SCT \[[@CR16]\]. But our study suggested that when the cytogenetic risk of patients belonged to MRC intermediate category and age were below 40 years-old, the patients who received induction chemotherapy without transplantation had a similar survival compared with the patients who underwent transplantation, the 3-year OS of both patients was 60--70%. The conclusion was also supported by the researches that were conducted in MD Anderson \[[@CR17]\]. Their data showed that the median OS of patients with AEL was 36 weeks and the diagnose of AEL did not imply a dismal outcome. Transplantation was a better choice for those whose cytogenetic category was unfavorable.

Conclusions {#Sec13}
===========

Following the new classification, there were no differences between MDS and AML subtype except for male/female ratio and age. Cytogenetic, rather than MDS/AML subtypes, can better represent the prognostic factor of previously diagnosed AEL patients. Transplantation was a better choice for those whose cytogenetic category was unfavorable.
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